To NASDAQ OMX Copenhagen A/S
Announcement no. 24-13 / Copenhagen, November 1, 2013
Topotarget announces its financial calendar for 2014 as follows:
Financial results for the full year 2013 January 30, 2014
Annual report 2013 March 27, 2014
Annual General Meeting 2014 April 24, 2014
Financial results for the first quarter 2014 May 8, 2014
Financial results for the first half of 2014 August 14, 2014
Financial results for the first nine months of 2014 November 6, 2014
Any issues from shareholders for the agenda of the Annual General Meeting must be submitted in writing to the Board of Directors no later than Thursday, March 13, 2014.
For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345
Topotarget (NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.